The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
|Videos|November 6, 2017
Dr. Hamlin on Key Points of a Study on Cerdulatinib in Non-Hodgkin Lymphoma
Author(s)Paul A. Hamlin, MD
Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.
Advertisement
Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.
There is an increasing amount of oral agents that will be available for patients with a good safety margin and the possibility of combinations, states Hamlin.
According to Hamlin, we are entering an era where the understanding of biology will allow us to address the patients
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.
Advertisement
Related to this article
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
R. Lor Randall, MD, FACS, outlines how AI may affect oncology training, how to properly work alongside AI, and AI-patient conversations.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Tegavivint Plus Osimertinib Shows Early Activity in First-Line EGFR-Mutated NSCLC
4
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
5